SCHEMBL23015809

SCHEMBL23015809

CCCc1cc(NC(N)=O)ccn1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.54
CYP3A4 P08684 1/20 0.54
TSHR P16473 1/20 0.54
PRKCI P41743 1/20 0.50
MAPT P10636 1/20 0.49
HSD17B10 Q99714 1/20 0.49
SREBF2 Q12772 2/20 0.44
ALDH1A1 P00352 1/20 0.44
NR3C2 P08235 7/20 0.43
AR P10275 2/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.41
EGFR P00533 1/20 0.40
MCHR1 Q99705 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27627388 0.87 PRKCI (0.63) KDM4ELMNACYP3A4TSHRPRKCI
SCHEMBL21982078 0.76 KDM4E (0.50) KDM4ELMNACYP3A4TSHRPRKCI
SCHEMBL4863259 0.76 S1PR1 (0.48) PRKCIMAPTHSD17B10ALDH1A1NR3C2
SCHEMBL17873933 0.76 KDM4E (0.73) KDM4ELMNACYP3A4TSHRHSD17B10
SCHEMBL6079794 0.75 MEN1 (0.41) KDM4EPRKCIMAPTHSD17B10ALDH1A1
SCHEMBL15880595 0.75 SMARCA2 (0.61) MAPTHSD17B10NR3C2
SCHEMBL15880501 0.73 PRKCI (0.62) LMNAPRKCIARCYP1A2POLB
SCHEMBL23015740 0.73 SREBF2 (0.57) KDM4ELMNACYP3A4TSHRMAPT
SCHEMBL2998832 0.73 KDM4E (0.64) KDM4ELMNACYP3A4TSHRPRKCI
SCHEMBL4701803 0.73 NR3C2 (0.55) NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927106-B2 Benzothiazole derivatives as DYRK1 inhibitors PHARMASUM THERAPEUTICS AS (NO) 2021-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927106-B2 Benzothiazole derivatives as DYRK1 inhibitors DYRK1A, DYRK1B, PDK2 KDM4E 984/4885LMNA 4785/4885CYP3A4 2557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.